Business
Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform
Conference Call Scheduled for Thursday, June 6 at 5:30am PT/8:30am ET SAN DIEGO, June 5, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO)
About this update from Halozyme Therapeutics, Inc.
[{"type":"text","content":"Conference Call Scheduled for Thursday, June 6 at 5:30am PT/8:30am ET\nSAN DIEGO, June 5, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (\"Halozyme\") today announced the grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20 product obtained from Halozyme's ENHANZE® manufacturing methods that the Company provides to its current and future licensees. The new patent is licensed under all of Halozyme's ENHANZE® licenses. It will be validated in 37 European countries and expires on March 6, 2029.\n\"This new European patent for ENHANZE further strengthens our robust patent estate and extends the durability of our portfolio,\" said Dr. Helen Torley, president and chief executive officer of Halozyme. \"We are pleased to be able to maintain the original royalty rate for DARZALEX SC in Europe through March 2029 based on this new patent.\"\nUnder the terms of Halozyme's ENHANZE® license with Janssen, the newly granted patent prevents the reduction in the royalty rate on sales of DARZALEX® SC in the European countries where it is validated until the patent expires. The new patent is not expected to have any impact to royalties under other ENHANZE® licenses with an issued or pending collaboration patent, as current royalty rates for these licenses are already expected to extend beyond expiration of the new patent. \nWebcast and Conference Call\nHalozyme will discuss the new European patent and provide an update to its 2024 financial guidance and 5-year financial outlook on a conference call tomorrow, Thursday, June 6 at 5:30am PT/8:30am ET. The call will be webcast live through the \"Investors\" section of Halozyme's corporate website and a recording will be made available following the completion of the call. To access the webcast and presentation, please visit ir.halozyme.com.\nThe call may also be accessed with the dial-in information below:\nParticipant Toll-Free Number: 888-632-3384Participant Direct/International Number: 785-424-1794Conference ID: HALO0624\nAbout Halozyme\nHalozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delive...